Dipartimento di Medicina e Scienze della Salute "Vincenzo Tiberio", Università degli Studi del Molise, Campobasso, Italy.
Inflammation and Immunology, Pfizer, Italy.
Clin Exp Rheumatol. 2018 Sep-Oct;36(5):900-910. Epub 2018 Mar 16.
It is currently recognised that remission can be an achievable target for several rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients by a treat-to-target approach. For RA different remission criteria have been proposed, depending on the disease activity scores used, on the importance given to the inclusion of patients' perspective into the definition of remission, and on their applicability in clinical practice, that generate highly different remission rates. Conversely, for PsA, remission is still insufficiently defined and represents a partially unmet need. For both conditions, several first- and second-line treatment strategies are now available - disease-modifying anti-rheumatic drugs (DMARDs) of synthetic and biologic origin - that make the achievement of remission or at least low/minimal disease activity a realistic goal. This paper is a narrative review of the different criteria of remission, in the light of the available treatment strategies for RA and PsA, and in the attempt to provide rheumatologists an opportunity to improve the outcome to the greatest extent possible in their clinical practice.
目前，通过靶向治疗，一些类风湿关节炎（RA）和银屑病关节炎（PsA）患者可以达到缓解的目标。针对 RA，已经提出了不同的缓解标准，这取决于所使用的疾病活动评分、将患者观点纳入缓解定义的重要性以及其在临床实践中的适用性，这些因素导致了高度不同的缓解率。相反，对于 PsA，缓解仍然没有得到充分定义，这是一个部分未满足的需求。对于这两种疾病，现在有多种一线和二线治疗策略——合成和生物来源的疾病修饰抗风湿药物（DMARDs）——这使得缓解或至少低/最小疾病活动成为一个现实的目标。本文是对 RA 和 PsA 现有治疗策略背景下缓解标准的叙述性综述，旨在为风湿病学家提供机会，使其在临床实践中尽可能提高治疗效果。
